{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:29:05Z","timestamp":1791660545253,"version":"4.3.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"This work was supported by a grant from Project of Science and Technology Department of Sichuan Province","award":["2020JDTD0036"],"award-info":[{"award-number":["2020JDTD0036"]}]},{"name":"This work was supported by a grant from Project of Science and Technology Department of Sichuan Province","award":["2020JDTD0036"],"award-info":[{"award-number":["2020JDTD0036"]}]},{"name":"This work was supported by a grant from Project of Science and Technology Department of Sichuan Province","award":["2020JDTD0036"],"award-info":[{"award-number":["2020JDTD0036"]}]},{"name":"This work was supported by a grant from Project of Science and Technology Department of Sichuan Province","award":["2020JDTD0036"],"award-info":[{"award-number":["2020JDTD0036"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02914-4","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T08:07:06Z","timestamp":1749802026000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Stereotactic body radiation therapy (SBRT) increases anti-PD-1 antitumor activity by enhancing the tumor immune microenvironment in mice with metastatic hepatocellular carcinoma"],"prefix":"10.1007","volume":"16","author":[{"given":"Ke","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingsheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuancheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanlin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinni","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingpeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunwei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"key":"2914_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71:209\u201349.","journal-title":"Cancer J Clin"},{"key":"2914_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/jcar.JCar_9_16","volume":"16","author":"YA Ghouri","year":"2017","unstructured":"Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J Carcinog. 2017;16:1.","journal-title":"J Carcinog"},{"key":"2914_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.","journal-title":"Nat Rev Dis Primers"},{"key":"2914_CR4","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/S0140-6736(21)01374-X","volume":"398","author":"P Gin\u00e8s","year":"2021","unstructured":"Gin\u00e8s P, Krag A, Abraldes JG, Sol\u00e0 E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet (London England). 2021;398:1359\u201376.","journal-title":"Lancet (London England)"},{"key":"2914_CR5","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.3748\/wjg.v24.i39.4436","volume":"24","author":"JM O\u2019Rourke","year":"2018","unstructured":"O\u2019Rourke JM, Sagar VM, Shah T, Shetty S. Carcinogenesis on the background of liver fibrosis: implications for the management of hepatocellular cancer. World J Gastroenterol. 2018;24:4436\u201347.","journal-title":"World J Gastroenterol"},{"key":"2914_CR6","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet (London England). 2018;391:1301\u201314.","journal-title":"Lancet (London England)"},{"key":"2914_CR7","doi-asserted-by":"publisher","first-page":"107327481772925","DOI":"10.1177\/1073274817729258","volume":"24","author":"D Zamora-Valdes","year":"2017","unstructured":"Zamora-Valdes D, Taner T, Nagorney DM. Surgical treatment of hepatocellular carcinoma. Cancer Control: J Moffitt Cancer Cent. 2017;24:1073274817729258.","journal-title":"Cancer Control: J Moffitt Cancer Cent"},{"key":"2914_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1053\/j.semdp.2016.12.011","volume":"34","author":"J Hartke","year":"2017","unstructured":"Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepatocellular carcinoma. Semin Diagn Pathol. 2017;34:153\u20139.","journal-title":"Semin Diagn Pathol"},{"key":"2914_CR9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1159\/000342402","volume":"1","author":"M Kudo","year":"2012","unstructured":"Kudo M. Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver cancer. 2012;1:62\u201370.","journal-title":"Liver cancer"},{"key":"2914_CR10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1159\/000496439","volume":"8","author":"M Bouattour","year":"2019","unstructured":"Bouattour M, Mehta N, He AR, Cohen EI, Nault JC. Systemic treatment for advanced hepatocellular carcinoma. Liver cancer. 2019;8:341\u201358.","journal-title":"Liver cancer"},{"key":"2914_CR11","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","volume":"57","author":"J Bruix","year":"2012","unstructured":"Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM. Efficacy and safety of Sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57:821\u20139.","journal-title":"J Hepatol"},{"key":"2914_CR12","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3350\/cmh.2020.0095","volume":"27","author":"GS Yoo","year":"2021","unstructured":"Yoo GS, Ahn WG, Kim SY, Kang W, Choi C, Park HC. Radiation-induced abscopal effect and its enhancement by programmed cell death 1 Blockade in the hepatocellular carcinoma: A murine model study. Clin Mol Hepatol. 2021;27:144\u201356.","journal-title":"Clin Mol Hepatol"},{"key":"2914_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1055\/s-0030-1247133","volume":"30","author":"A Forner","year":"2010","unstructured":"Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30:61\u201374.","journal-title":"Semin Liver Dis"},{"key":"2914_CR14","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus Sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet (London England). 2018;391:1163\u201373.","journal-title":"Lancet (London England)"},{"key":"2914_CR15","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1111\/liv.14817","volume":"41","author":"A Casadei-Gardini","year":"2021","unstructured":"Casadei-Gardini A, Scartozzi M, Tada T, Yoo C, Shimose S, Masi G, Lonardi S, Frassineti LG, Nicola S, Piscaglia F, Kumada T, Kim HD, Koga H, Vivaldi C, Sold\u00e0 C, Hiraoka A, Bang Y, Atsukawa M, Torimura T, Tsuj K, Itobayashi E, Toyoda H, Fukunishi S, Rimassa L, Rimini M, Cascinu S, Cucchetti A. Lenvatinib versus Sorafenib in first-line treatment of unresectable hepatocellular carcinoma: an inverse probability of treatment weighting analysis. Liver Int: Off J Int Assoc Study Liver. 2021;41:1389\u201397.","journal-title":"Liver Int: Off J Int Assoc Study Liver"},{"key":"2914_CR16","first-page":"188638","volume":"1876","author":"Y Zheng","year":"2021","unstructured":"Zheng Y, Wang S, Cai J, Ke A, Fan J. The progress of immune checkpoint therapy in primary liver cancer. Biochimica et biophysica acta. Reviews cancer. 2021;1876:188638.","journal-title":"Reviews cancer"},{"key":"2914_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.canlet.2019.11.009","volume":"470","author":"X Lei","year":"2020","unstructured":"Lei X, Lei Y, Li JK, Du WX, Li RG, Yang J, Li J, Li F, Tan HB. Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy. Cancer Lett. 2020;470:126\u201333.","journal-title":"Cancer Lett"},{"key":"2914_CR18","first-page":"2326","volume":"35","author":"Z Shen","year":"2019","unstructured":"Shen Z, Li M, Bai S, Yang Q, Zhang F, Tang M, Guo J, Yang Z. [Progress in immunotherapy for hepatocellular carcinoma]. Sheng Wu Gong Cheng Xue bao\u2009=\u2009chinese. J Biotechnol. 2019;35:2326\u201338.","journal-title":"J Biotechnol"},{"key":"2914_CR19","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1007\/s11427-018-9446-2","volume":"62","author":"M Tian","year":"2019","unstructured":"Tian M, Shi Y, Liu W, Fan J. Immunotherapy of hepatocellular carcinoma: strategies for combinatorial intervention. Sci China Life Sci. 2019;62:1138\u201343.","journal-title":"Sci China Life Sci"},{"key":"2914_CR20","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nrc.2018.6","volume":"18","author":"W Ngwa","year":"2018","unstructured":"Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC. Using immunotherapy to boost the abscopal effect. Nat Rev Cancer. 2018;18:313\u201322.","journal-title":"Nat Rev Cancer"},{"key":"2914_CR21","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.it.2018.06.001","volume":"39","author":"ME Rodr\u00edguez-Ruiz","year":"2018","unstructured":"Rodr\u00edguez-Ruiz ME, Vanpouille-Box C, Melero I, Formenti SC, Demaria S. Immunological mechanisms responsible for Radiation-Induced abscopal effect. Trends Immunol. 2018;39:644\u201355.","journal-title":"Trends Immunol"},{"key":"2914_CR22","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJMoa1112824","volume":"366","author":"MA Postow","year":"2012","unstructured":"Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, Yang AS, Roman RA, Rosner S, Benson B, Allison JP, Lesokhin AM, Gnjatic S, Wolchok JD. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925\u201331.","journal-title":"N Engl J Med"},{"key":"2914_CR23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.canlet.2020.12.045","volume":"502","author":"NE Donlon","year":"2021","unstructured":"Donlon NE, Power R, Hayes C, Reynolds JV, Lysaght J. Radiotherapy, immunotherapy, and the tumour microenvironment: turning an immunosuppressive milieu into a therapeutic opportunity. Cancer Lett. 2021;502:84\u201396.","journal-title":"Cancer Lett"},{"key":"2914_CR24","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1038\/s41467-019-11906-2","volume":"10","author":"A Arina","year":"2019","unstructured":"Arina A, Beckett M, Fernandez C, Zheng W, Pitroda S, Chmura SJ, Luke JJ, Forde M, Hou Y, Burnette B, Mauceri H, Lowy I, Sims T, Khodarev N, Fu YX, Weichselbaum RR. Tumor-reprogrammed resident T cells resist radiation to control tumors. Nat Commun. 2019;10:3959.","journal-title":"Nat Commun"},{"key":"2914_CR25","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/j.ejca.2007.05.028","volume":"43","author":"N Meister","year":"2007","unstructured":"Meister N, Shalaby T, von Bueren AO, Rivera P, Patti R, Oehler C, Pruschy M, Grotzer MA. Interferon-gamma mediated up-regulation of caspase-8 sensitizes Medulloblastoma cells to radio- and chemotherapy. Eur J cancer (Oxford England: 1990). 2007;43:1833\u201341.","journal-title":"Eur J cancer (Oxford England: 1990)"},{"key":"2914_CR26","first-page":"365","volume":"14","author":"RR Weichselbaum","year":"2017","unstructured":"Weichselbaum RR, Liang H, Deng L, Fu YX. Radiotherapy and immunotherapy: a beneficial liaison? Nature reviews. Clin Oncol. 2017;14:365\u201379.","journal-title":"Clin Oncol"},{"key":"2914_CR27","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.3748\/wjg.v25.i20.2416","volume":"25","author":"C Choi","year":"2019","unstructured":"Choi C, Yoo GS, Cho WK, Park HC. Optimizing radiotherapy with immune checkpoint Blockade in hepatocellular carcinoma. World J Gastroenterol. 2019;25:2416\u201329.","journal-title":"World J Gastroenterol"},{"key":"2914_CR28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-020-00940-z","volume":"13","author":"Y Chen","year":"2020","unstructured":"Chen Y, Gao M, Huang Z, Yu J, Meng X. SBRT combined with PD-1\/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges. J Hematol Oncol. 2020;13:105.","journal-title":"J Hematol Oncol"},{"key":"2914_CR29","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1172\/JCI96582","volume":"128","author":"X Zheng","year":"2018","unstructured":"Zheng X, Fang Z, Liu X, Deng S, Zhou P, Wang X, Zhang C, Yin R, Hu H, Chen X, Han Y, Zhao Y, Lin SH, Qin S, Wang X, Kim BY, Zhou P, Jiang W, Wu Q, Huang Y. Increased vessel perfusion predicts the efficacy of immune checkpoint Blockade. J Clin Investig. 2018;128:2104\u201315.","journal-title":"J Clin Investig"},{"key":"2914_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.20.02046","volume":"39","author":"TY Seiwert","year":"2021","unstructured":"Seiwert TY, Kiess AP. Time to debunk an urban myth?? The abscopal effect with radiation and Anti-PD-1. J Clin Oncol: Off J Am Soc Clin Oncol. 2021;39:1\u20133.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"2914_CR31","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","volume":"74","author":"SJ Dovedi","year":"2014","unstructured":"Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, Stratford IJ, Poon E, Morrow M, Stewart R, Jones H, Wilkinson RW, Honeychurch J, Illidge TM. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 Blockade. Cancer Res. 2014;74:5458\u201368.","journal-title":"Cancer Res"},{"key":"2914_CR32","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"EASL Clinical Practice Guidelines","year":"2018","unstructured":"EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69:182\u2013236.","journal-title":"J Hepatol"},{"key":"2914_CR33","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","volume":"21","author":"S Qin","year":"2020","unstructured":"Qin S, Ren Z, Meng Z, Chen Z, Chai X, Xiong J, Bai Y, Yang L, Zhu H, Fang W, Lin X, Chen X, Li E, Wang L, Chen C, Zou J. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020;21:571\u201380.","journal-title":"Lancet Oncol"},{"key":"2914_CR34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.19.01307","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox J, Daniele B, Ebbinghaus SW, Chen E, Siegel AB, Zhu AX, Cheng AL. Pembrolizumab as Second-Line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol: Off J Am Soc Clin Oncol. 2020;38:193\u2013202.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"2914_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12943-021-01317-7","volume":"20","author":"JY Li","year":"2021","unstructured":"Li JY, Chen YP, Li YQ, Liu N, Ma J. Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint Blockades. Mol Cancer. 2021;20:27.","journal-title":"Mol Cancer"},{"key":"2914_CR36","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","volume":"14","author":"S Zhu","year":"2021","unstructured":"Zhu S, Zhang T, Zheng L, Liu H, Song W, Liu D, Li Z, Pan CX. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol. 2021;14:156.","journal-title":"J Hematol Oncol"},{"key":"2914_CR37","doi-asserted-by":"publisher","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","volume":"2","author":"A Haslam","year":"2019","unstructured":"Haslam A, Prasad V. Estimation of the percentage of US patients with Cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2:e192535.","journal-title":"JAMA Netw Open"},{"key":"2914_CR38","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1126\/science.1232458","volume":"339","author":"L Sun","year":"2013","unstructured":"Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Sci (New York N Y). 2013;339:786\u201391.","journal-title":"Sci (New York N Y)"},{"key":"2914_CR39","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.immuni.2018.09.016","volume":"49","author":"A Marcus","year":"2018","unstructured":"Marcus A, Mao AJ, Lensink-Vasan M, Wang L, Vance RE, Raulet DH. Tumor-Derived cGAMP triggers a STING-Mediated interferon response in Non-tumor cells to activate the NK cell response. Immunity. 2018;49:754\u2013e7634.","journal-title":"Immunity"},{"key":"2914_CR40","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1158\/2326-6066.CIR-17-0581","volume":"6","author":"JM Diamond","year":"2018","unstructured":"Diamond JM, Vanpouille-Box C, Spada S, Rudqvist NP, Chapman JR, Ueberheide BM, Pilones KA, Sarfraz Y, Formenti SC, Demaria S. Exosomes shuttle TREX1-Sensitive IFN-Stimulatory DsDNA from irradiated Cancer cells to DCs. Cancer Immunol Res. 2018;6:910\u201320.","journal-title":"Cancer Immunol Res"},{"key":"2914_CR41","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","volume":"167","author":"JL Benci","year":"2016","unstructured":"Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, Cucolo L, Lee DSM, Pauken KE, Huang AC, Gangadhar TC, Amaravadi RK, Schuchter LM, Feldman MD, Ishwaran H, Vonderheide RH, Maity A, Wherry EJ. Minn, tumor interferon signaling regulates a Multigenic resistance program to immune checkpoint Blockade. Cell. 2016;167:1540\u2013e155412.","journal-title":"Cell"},{"key":"2914_CR42","doi-asserted-by":"publisher","first-page":"650394","DOI":"10.3389\/fonc.2021.650394","volume":"11","author":"Y Huang","year":"2021","unstructured":"Huang Y, Zhang Z, Liao W, Hu K, Wang Z. Combination of sorafenib, camrelizumab, transcatheter arterial chemoembolization, and stereotactic body radiation therapy as a novel downstaging strategy in advanced hepatocellular carcinoma with portal vein tumor thrombus: A case series study. Front Oncol. 2021;11:650394.","journal-title":"Front Oncol"},{"issue":"4","key":"2914_CR43","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1159\/000490260","volume":"8","author":"D Bettinger","year":"2019","unstructured":"Bettinger D, Pinato DJ, Schultheiss M, et al. Stereotactic body radiation therapy as an alternative treatment for patients with hepatocellular carcinoma compared to sorafenib: A propensity score analysis. Liver Cancer. 2019;8(4):281\u201394.","journal-title":"Liver Cancer"},{"key":"2914_CR44","doi-asserted-by":"publisher","first-page":"7516","DOI":"10.4049\/jimmunol.174.12.7516","volume":"174","author":"AA Lugade","year":"2005","unstructured":"Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005;174:7516\u201323.","journal-title":"J Immunol"},{"issue":"8","key":"2914_CR45","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/nrclinonc.2016.30","volume":"13","author":"MB Bernstein","year":"2016","unstructured":"Bernstein MB, Krishnan S, Hodge JW, Chang JY. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol. 2016;13(8):516\u201324.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"2914_CR46","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687\u201395.","journal-title":"J Clin Invest"},{"key":"2914_CR47","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","volume":"15","author":"MZ Dewan","year":"2009","unstructured":"Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, Demaria S. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res: Off J Am Assoc Cancer Res. 2009;15:5379\u201388.","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"2914_CR48","doi-asserted-by":"publisher","first-page":"e000537","DOI":"10.1136\/jitc-2020-000537","volume":"8","author":"HB Barsoumian","year":"2020","unstructured":"Barsoumian HB, Ramapriyan R, Younes AI, Caetano MS, Menon H, Comeaux NI, Cushman TR, Schoenhals JE, Cadena AP, Reilly TP, Chen D, Masrorpour F, Li A, Hong DS, Diab A, Nguyen QN, Glitza I, Ferrarotto R, Chun SG, Cortez MA, Welsh J. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer. 2020;8:e000537.","journal-title":"J Immunother Cancer"},{"key":"2914_CR49","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41586-021-03614-z","volume":"594","author":"AL Correia","year":"2021","unstructured":"Correia AL, Guimaraes JC, Auf der Maur P, De Silva D, Trefny MP, Okamoto R, Bruno S, Schmidt A, Mertz K, Volkmann K, Terracciano L, Zippelius A, Vetter M, Kurzeder C, Weber WP. Bentires-Alj, hepatic stellate cells suppress NK cell-sustained breast cancer dormancy. Nature. 2021;594:566\u201371.","journal-title":"Nature"},{"key":"2914_CR50","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-Related adverse events associated with immune checkpoint Blockade. N Engl J Med. 2018;378:158\u201368.","journal-title":"N Engl J Med"},{"key":"2914_CR51","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/pro6.1233","volume":"8","author":"J Yan","year":"2024","unstructured":"Yan J, Sui J. Long-term survival after immunotherapy for uncontrolled locally advanced Temporal bone squamous cell carcinoma followed by chemoradiotherapy: A case report. Prec Radiat Oncol. 2024;8:99\u2013105.","journal-title":"Prec Radiat Oncol"},{"key":"2914_CR52","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/pro6.1225","volume":"8","author":"K Meng","year":"2024","unstructured":"Meng K, Lu H. Clinical application of high-LET radiotherapy combined with immunotherapy in malignant tumors. Prec Radiat Oncol. 2024;8:42\u20136.","journal-title":"Prec Radiat Oncol"},{"key":"2914_CR53","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/pro6.1220","volume":"8","author":"D Nakamura","year":"2024","unstructured":"Nakamura D, Honda K, Yamazaki T, et al. Stereotactic body radiation therapy for clinically diagnosed early-stage non-small cell lung cancer: importance of accurate CT interpretation by experts. Prec Radiat Oncol. 2024;8:30\u20136.","journal-title":"Prec Radiat Oncol"},{"key":"2914_CR54","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Ch\u00e1vez A, Keegan N, Khamashta MA, Lambotte O, Mariette X, Su\u00e1rez-Almazor PA. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6:38.","journal-title":"Nat Rev Dis Primers"},{"key":"2914_CR55","first-page":"375","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr., Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. The lancet. Oncology. 2015;16:375\u201384.","journal-title":"Oncology"},{"key":"2914_CR56","doi-asserted-by":"publisher","first-page":"116129","DOI":"10.1016\/j.ejmech.2024.116129","volume":"265","author":"B Cheng","year":"2024","unstructured":"Cheng B, Pan W, Xiao Y, et al. HDAC-targeting epigenetic modulators for cancer immunotherapy. Eur J Med Chem. 2024;265:116129.","journal-title":"Eur J Med Chem"},{"key":"2914_CR57","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.omto.2020.08.017","volume":"19","author":"R Han","year":"2020","unstructured":"Han R, Nusbaum O, Chen X, Zhu Y. Valeric acid suppresses liver cancer development by acting as a novel HDAC inhibitor. Mol Ther Oncol. 2020;19:8\u201318.","journal-title":"Mol Ther Oncol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02914-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02914-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02914-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T09:02:39Z","timestamp":1749805359000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02914-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2914"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02914-4","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]},"assertion":[{"value":"28 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial complied with the Declaration of Helsinki and was approved by the Clinical Trials Ethics Committee of the Affiliated Hospital of Southwest Medical University (Approval No. KY2020254). Due to the retrospective nature of the study, the requirement for informed consent was waived by the Ethics Committee of the Affiliated Hospital of Southwest Medical University. No potentially identifying information or images of human participants are included in this article. All methods were carried out in accordance with relevant guidelines and regulations. The study conforms to the ARIVE guidelines and should be carried out in accordance with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards, the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines(). EU Directive 2010\/63\/EU for animal experiments, or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978). The Ethics Committee of Southwest Medical University (SWMU) stipulates that the Ethics Committee allows a tumor load of 2\u00a0cm or approximately 10% of the body weight of the mice, and the tumor sizes during tumor modeling of the mice involved in this study were in accordance with the regulations of the Ethics Committee of Southwest Medical University. Animal experiments were carried out in accordance with animal care guidelines and were authorized by the Institutional Animal Care and Treatment Committee of Southwest Medical University (Luzhou, China) (approval No. SWMU20220042).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1081"}}